ES2602585T3 - Vectores de baculovirus que comprenden secuencias de codificación repetidas con sesgos de codones diferenciales - Google Patents
Vectores de baculovirus que comprenden secuencias de codificación repetidas con sesgos de codones diferenciales Download PDFInfo
- Publication number
- ES2602585T3 ES2602585T3 ES08779058.0T ES08779058T ES2602585T3 ES 2602585 T3 ES2602585 T3 ES 2602585T3 ES 08779058 T ES08779058 T ES 08779058T ES 2602585 T3 ES2602585 T3 ES 2602585T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- sequences
- sequence
- rep52
- rep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95208107P | 2007-07-26 | 2007-07-26 | |
| US952081P | 2007-07-26 | ||
| EP07113257 | 2007-07-26 | ||
| EP07113257 | 2007-07-26 | ||
| PCT/NL2008/050512 WO2009014445A2 (en) | 2007-07-26 | 2008-07-25 | Baculoviral vectors comprising repeated coding sequences with differential codon biases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2602585T3 true ES2602585T3 (es) | 2017-02-21 |
Family
ID=38753583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08779058.0T Active ES2602585T3 (es) | 2007-07-26 | 2008-07-25 | Vectores de baculovirus que comprenden secuencias de codificación repetidas con sesgos de codones diferenciales |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8697417B2 (OSRAM) |
| EP (3) | EP3561063A1 (OSRAM) |
| JP (2) | JP5634262B2 (OSRAM) |
| KR (1) | KR101597695B1 (OSRAM) |
| CN (1) | CN101868547B (OSRAM) |
| AU (1) | AU2008279883B2 (OSRAM) |
| BR (1) | BRPI0814459B1 (OSRAM) |
| CA (1) | CA2694406C (OSRAM) |
| DK (2) | DK2173888T3 (OSRAM) |
| EA (1) | EA022169B1 (OSRAM) |
| ES (1) | ES2602585T3 (OSRAM) |
| HU (1) | HUE029744T2 (OSRAM) |
| IL (1) | IL203535A (OSRAM) |
| MX (1) | MX2010000944A (OSRAM) |
| NZ (1) | NZ582881A (OSRAM) |
| PL (2) | PL2173888T3 (OSRAM) |
| PT (1) | PT2173888T (OSRAM) |
| SI (2) | SI2173888T1 (OSRAM) |
| WO (1) | WO2009014445A2 (OSRAM) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2173888T (pt) * | 2007-07-26 | 2016-11-17 | Uniqure Ip Bv | Resumo |
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| US9228174B2 (en) * | 2010-03-11 | 2016-01-05 | Uniqure Ip B.V. | Mutated rep encoding sequences for use in AAV production |
| WO2011122950A1 (en) | 2010-04-01 | 2011-10-06 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Monomeric duplex aav vectors |
| IT1400425B1 (it) | 2010-06-08 | 2013-05-31 | Amsterdam Molecular Therapeutics Bv | Modified snrnas for use in therapy. |
| WO2012145509A2 (en) | 2011-04-19 | 2012-10-26 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors, and viruses |
| GB201210357D0 (en) | 2012-06-12 | 2012-07-25 | Ucl Business Plc | Factor VIII sequences |
| WO2015060722A1 (en) | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| ES2990174T3 (es) | 2014-03-10 | 2024-11-29 | Uniqure Ip Bv | Vectores de AAV mejorados producidos en células de insecto |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| KR20170096998A (ko) | 2014-11-05 | 2017-08-25 | 보이저 테라퓨틱스, 인크. | 파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| WO2016077687A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016077689A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| DK3224376T4 (da) | 2014-11-28 | 2023-05-30 | Uniqure Ip Bv | DNA-forureninger i en sammensætning omfattende en parvoviral virion |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| EA037696B1 (ru) | 2014-12-24 | 2021-05-12 | ЮНИКЕР АйПи Б.В. | Супрессия гена гентингтина, индуцированная рнк-интерференцией |
| JP7496667B2 (ja) * | 2016-04-21 | 2024-06-07 | ビロベク，インコーポレイテッド | 昆虫細胞中でのａａｖ生成、方法およびその組成物 |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| BR112018073472A2 (pt) | 2016-05-18 | 2019-08-27 | Voyager Therapeutics Inc | composições e métodos de tratamento da doença de huntington |
| EP3491008A2 (en) * | 2016-07-26 | 2019-06-05 | BioMarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
| EP3510161A4 (en) | 2016-08-23 | 2020-04-22 | Akouos, Inc. | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT |
| JP2019531787A (ja) | 2016-08-30 | 2019-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム |
| CA3045551A1 (en) | 2016-12-16 | 2018-06-21 | Uniqure Ip B.V. | Immunoadsorption |
| WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| SG11201909868YA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| IL271957B2 (en) | 2017-07-10 | 2024-02-01 | Uniqure Ip Bv | Means and methods for AAV-based gene therapy |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CA3075656A1 (en) | 2017-09-29 | 2019-04-04 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| EP4454654A3 (en) | 2017-10-16 | 2025-02-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| CN111527201A (zh) | 2017-12-29 | 2020-08-11 | 优尼科Ip有限公司 | 修饰的病毒载体及其制备和使用方法 |
| LT3740222T (lt) | 2018-01-17 | 2023-09-11 | Meiragtx Uk Ii Limited | Modifikuotas raav kapsidės baltymas, skirtas genų terapijai |
| GB201800903D0 (en) | 2018-01-19 | 2018-03-07 | Oxford Genetics Ltd | Vectors |
| JP2021523914A (ja) | 2018-05-15 | 2021-09-09 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | パーキンソン病を治療するための組成物および方法 |
| TW202015742A (zh) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | 投遞腺相關病毒（ａａｖ）之組成物和方法 |
| US12060567B2 (en) | 2018-06-13 | 2024-08-13 | Voyager Therapeutics, Inc. | Engineered untranslated regions (UTR) for AAV production |
| JP7565218B2 (ja) | 2018-07-02 | 2024-10-10 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症および脊髄に関連する障害の治療 |
| US20210355454A1 (en) | 2018-07-24 | 2021-11-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| CA3112007A1 (en) | 2018-09-12 | 2020-03-19 | Uniqure Ip B.V. | Rnai induced c9orf72 suppression for the treatment of als/ftd |
| WO2020061418A1 (en) * | 2018-09-20 | 2020-03-26 | Tallgrass Biologics L.L.C. | Treatment and control of colony collapse disorder |
| CN109295172A (zh) * | 2018-09-26 | 2019-02-01 | 浙江海洋大学 | 大黄鱼清道夫受体家族基因的密码子偏好性分析方法 |
| JP7528066B2 (ja) | 2018-09-28 | 2024-08-05 | ボイジャー セラピューティクス インコーポレイテッド | 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法 |
| US20210348242A1 (en) | 2018-10-04 | 2021-11-11 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| AU2019354793A1 (en) | 2018-10-05 | 2021-05-13 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding AAV production proteins |
| WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| EP3867389A1 (en) | 2018-10-15 | 2021-08-25 | Voyager Therapeutics, Inc. | Expression vectors for large-scale production of raav in the baculovirus/sf9 system |
| EP3884050A1 (en) | 2018-11-19 | 2021-09-29 | uniQure IP B.V. | Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3 |
| WO2020104435A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | A companion diagnostic to monitor the effects of gene therapy |
| WO2020104480A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Biopharma B.V. | Adeno-associated virus vectors for expressing fviii mimetics and uses thereof |
| AU2019382824A1 (en) | 2018-11-19 | 2021-06-03 | Uniqure Ip B.V. | Method and means to deliver miRNA to target cells |
| US20220064671A1 (en) | 2019-01-18 | 2022-03-03 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| EP3962536A1 (en) | 2019-04-29 | 2022-03-09 | Voyager Therapeutics, Inc. | Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors |
| CA3146791A1 (en) | 2019-07-15 | 2021-01-21 | Meiragtx Uk Ii Limited | Modified aav capsid proteins for treatment of arthritic disease |
| WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| TW202122582A (zh) | 2019-08-26 | 2021-06-16 | 美商航海家醫療公司 | 病毒蛋白之控制表現 |
| WO2021041375A1 (en) * | 2019-08-26 | 2021-03-04 | Rootpath Genomics, Inc. | Compositions and methods for producing adeno-associated viral vectors |
| WO2021053018A1 (en) | 2019-09-16 | 2021-03-25 | Uniqure Ip B.V. | Targeting misspliced transcripts in genetic disorders |
| WO2021113767A1 (en) * | 2019-12-04 | 2021-06-10 | Sangamo Therapeutics, Inc. | Novel compositions and methods for producing recombinant aav |
| BR112022016596A2 (pt) | 2020-02-21 | 2022-11-16 | Akouos Inc | Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano |
| WO2021195491A2 (en) * | 2020-03-26 | 2021-09-30 | Asklepios Biopharmaceutical, Inc. | Inducible promoter for viral vector production |
| EP4127146A1 (en) | 2020-04-02 | 2023-02-08 | uniQure biopharma B.V. | Novel cell line |
| CA3169087A1 (en) * | 2020-04-02 | 2021-10-07 | David Johannes Francois DU PLESSIS | Dual bifunctional vectors for aav production |
| WO2021204872A1 (en) | 2020-04-07 | 2021-10-14 | Uniqure Ip B.V. | Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof |
| WO2021211753A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| US20230285596A1 (en) | 2020-07-27 | 2023-09-14 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| EP4189095A1 (en) | 2020-07-27 | 2023-06-07 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
| US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| US20240141377A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| EP4305157A1 (en) | 2021-03-09 | 2024-01-17 | Huidagene Therapeutics (Singapore) Pte. Ltd. | Engineered crispr/cas13 system and uses thereof |
| WO2022214635A1 (en) | 2021-04-08 | 2022-10-13 | Stichting Vu | Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders |
| AU2022285138A1 (en) | 2021-06-02 | 2023-11-30 | Uniqure Biopharma B.V. | Adeno-associated virus vectors modified to bind high-density lipoprotein |
| WO2022253955A2 (en) | 2021-06-02 | 2022-12-08 | Uniqure Biopharma B.V. | Insect cell production of parvoviral vectors with modified capsid proteins |
| US20250382611A1 (en) | 2021-06-21 | 2025-12-18 | Uniqure Biopharma B.V. | Gene constructs for silencing alpha-synuclein and uses thereof |
| CN117836010A (zh) | 2021-06-21 | 2024-04-05 | 优尼科生物制药有限公司 | 改进的裂解程序 |
| WO2023283962A1 (en) | 2021-07-16 | 2023-01-19 | Huigene Therapeutics Co., Ltd. | Modified aav capsid for gene therapy and methods thereof |
| AU2022317647A1 (en) * | 2021-07-28 | 2024-01-25 | Biomarin Pharmaceutical Inc. | Large scale adeno-associated virus production systems |
| EP4392434A1 (en) | 2021-08-26 | 2024-07-03 | uniQure biopharma B.V. | Insect cell-produced high potency aav vectors with cns-tropism |
| WO2023091949A2 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| EP4469585A2 (en) | 2022-01-25 | 2024-12-04 | Voyager Therapeutics, Inc. | Baculovirus expression system |
| CN114703203B (zh) * | 2022-02-11 | 2024-08-06 | 上海渤因生物科技有限公司 | 杆状病毒载体及其用途 |
| JP2025513066A (ja) | 2022-04-12 | 2025-04-22 | ユニキュアー バイオファーマ ビー．ブイ． | Ａｐｏｅの核酸制御 |
| US20250297252A1 (en) | 2022-04-12 | 2025-09-25 | Uniqure Biopharma B.V. | Nucleic acid regulation of SNCA |
| US20250230437A1 (en) | 2022-04-12 | 2025-07-17 | Uniqure Biopharma B.V. | Novel systems for nucleic acid regulation |
| WO2023198702A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of c9orf72 |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2024143440A1 (ja) | 2022-12-28 | 2024-07-04 | 富士フイルム株式会社 | アデノ随伴ウイルスの製造方法、およびベクターのセット |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2024218192A1 (en) | 2023-04-18 | 2024-10-24 | Uniqure Biopharma B.V. | Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs |
| WO2024218190A1 (en) | 2023-04-18 | 2024-10-24 | Uniqure Biopharma B.V. | Generation of adeno-associated virus capsid libraries for insect cells |
| AU2024256392A1 (en) | 2023-04-18 | 2025-10-23 | Uniqure Biopharma B.V. | Gene delivery vehicles comprising rna and antibodies |
| WO2024226761A2 (en) | 2023-04-26 | 2024-10-31 | Voyager Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| WO2024261220A1 (en) | 2023-06-23 | 2024-12-26 | Uniqure Biopharma B.V. | Novel fragile x constructs |
| WO2025049993A1 (en) | 2023-08-31 | 2025-03-06 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2025051805A1 (en) | 2023-09-04 | 2025-03-13 | Uniqure Biopharma B.V. | Novel neurotropic recombinant adeno-associated virus particles |
| WO2025078606A1 (en) | 2023-10-11 | 2025-04-17 | Uniqure Biopharma B.V. | Further novel systems for nucleic acid regulation |
| WO2025078598A1 (en) | 2023-10-11 | 2025-04-17 | Uniqure Biopharma B.V. | Novel nucleic acid regulation of huntingtin gene |
| WO2025078602A1 (en) | 2023-10-11 | 2025-04-17 | Uniqure Biopharma B.V. | Nucleic acid regulation of msh3 in repeat expansion disorders |
| WO2025114524A1 (en) | 2023-11-30 | 2025-06-05 | Uniqure Biopharma B.V. | Formulations for viral drug products |
| WO2025171227A1 (en) | 2024-02-08 | 2025-08-14 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2025219443A1 (en) | 2024-04-19 | 2025-10-23 | Uniqure Biopharma B.V. | Nucleic acid for a1at regulation |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5871974A (en) * | 1990-09-28 | 1999-02-16 | Ixsys Inc. | Surface expression libraries of heteromeric receptors |
| NZ308772A (en) * | 1995-05-17 | 1999-04-29 | Du Pont | Recombinant baculovirus insecticides |
| FR2774699B1 (fr) | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | Methode de reduction des evenements de recombinaison homologue |
| AU6490699A (en) | 1998-09-24 | 2000-04-10 | Ultrasonus Ab | A mixing method and a mixing chamber |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| ATE404217T1 (de) | 1999-06-24 | 2008-08-15 | Univ British Columbia | Therapie mit lipoproteinlipase (lpl) variant |
| WO2001014539A2 (en) * | 1999-08-20 | 2001-03-01 | Johns Hopkins University School Of Medicine | Methods and compositions for the construction and use of fusion libraries |
| WO2001068888A2 (en) * | 2000-03-14 | 2001-09-20 | Neurologix, Inc. | Production of chimeric capsid vectors |
| US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
| EP1572893B1 (en) | 2001-11-09 | 2009-01-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES | Production of adeno-associated virus in insect cells |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| CA2369985A1 (en) * | 2002-01-18 | 2003-07-18 | Duke University | Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach |
| AU2003217413A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Method for isolation and purification of expressed gene products in vitro |
| AU2003212708A1 (en) | 2002-03-05 | 2003-09-16 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| AU2003272868A1 (en) * | 2003-10-15 | 2005-04-27 | Agtc Gene Technology Company Ltd. | Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors |
| US20060166363A1 (en) * | 2004-01-27 | 2006-07-27 | Sergei Zolotukhin | Modified baculovirus expression system for production of pseudotyped rAAV vector |
| AU2005270430B2 (en) | 2004-08-03 | 2008-06-12 | Geneart Ag | Method for modulating gene expression by modifying the CpG content |
| PL1945779T3 (pl) | 2005-10-20 | 2013-08-30 | Uniqure Ip Bv | Ulepszone wektory AAV produkowane w komórkach owadzich |
| WO2007084773A2 (en) * | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
| CA2655957C (en) | 2006-06-21 | 2016-05-03 | Amsterdam Molecular Therapeutics (Amt) B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
| PT2173888T (pt) * | 2007-07-26 | 2016-11-17 | Uniqure Ip Bv | Resumo |
-
2008
- 2008-07-25 PT PT87790580T patent/PT2173888T/pt unknown
- 2008-07-25 SI SI200831676A patent/SI2173888T1/sl unknown
- 2008-07-25 NZ NZ582881A patent/NZ582881A/en unknown
- 2008-07-25 EA EA201070184A patent/EA022169B1/ru not_active IP Right Cessation
- 2008-07-25 WO PCT/NL2008/050512 patent/WO2009014445A2/en not_active Ceased
- 2008-07-25 EP EP19170381.8A patent/EP3561063A1/en active Pending
- 2008-07-25 EP EP16176100.2A patent/EP3093345B8/en active Active
- 2008-07-25 PL PL08779058T patent/PL2173888T3/pl unknown
- 2008-07-25 DK DK08779058.0T patent/DK2173888T3/en active
- 2008-07-25 PL PL16176100T patent/PL3093345T3/pl unknown
- 2008-07-25 SI SI200832065T patent/SI3093345T1/sl unknown
- 2008-07-25 US US12/670,780 patent/US8697417B2/en active Active
- 2008-07-25 CN CN200880108079.2A patent/CN101868547B/zh active Active
- 2008-07-25 DK DK16176100.2T patent/DK3093345T3/da active
- 2008-07-25 BR BRPI0814459-1A patent/BRPI0814459B1/pt active IP Right Grant
- 2008-07-25 KR KR1020107003963A patent/KR101597695B1/ko active Active
- 2008-07-25 JP JP2010518140A patent/JP5634262B2/ja active Active
- 2008-07-25 EP EP08779058.0A patent/EP2173888B1/en active Active
- 2008-07-25 AU AU2008279883A patent/AU2008279883B2/en active Active
- 2008-07-25 HU HUE08779058A patent/HUE029744T2/en unknown
- 2008-07-25 MX MX2010000944A patent/MX2010000944A/es active IP Right Grant
- 2008-07-25 CA CA2694406A patent/CA2694406C/en active Active
- 2008-07-25 ES ES08779058.0T patent/ES2602585T3/es active Active
-
2010
- 2010-01-26 IL IL203535A patent/IL203535A/en active IP Right Grant
-
2014
- 2014-02-27 US US14/192,101 patent/US9580691B2/en active Active
- 2014-07-14 JP JP2014144592A patent/JP2014239686A/ja active Pending
-
2015
- 2015-09-30 US US14/870,614 patent/US10190098B2/en active Active
-
2018
- 2018-12-11 US US16/216,775 patent/US11306291B2/en active Active
-
2022
- 2022-04-15 US US17/722,275 patent/US12486496B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2602585T3 (es) | Vectores de baculovirus que comprenden secuencias de codificación repetidas con sesgos de codones diferenciales | |
| CN112194706B (zh) | 腺相关病毒突变体及其应用 | |
| JP6366581B2 (ja) | 改変されたアデノ随伴ウイルスベクター組成物 | |
| CN111183225B (zh) | 在昆虫细胞中改进的aav衣壳产生 | |
| ES2785223T3 (es) | Células de insecto para la producción de vectores de AAV | |
| ES2467156T3 (es) | Una biblioteca de genes estructurales modificados o de partículas modificadas de cápside útiles para la identificación de clones virales con tropismo celular deseado | |
| ES2410133T3 (es) | Vectores de VAA mejorados producidos en células de insecto. | |
| AU2018323049B2 (en) | Adeno-associated virus (AAV) with modified phospholipase domain | |
| EA035747B1 (ru) | Днк-примеси в композиции, содержащей парвовирусный вирион | |
| CN115867647A (zh) | 新型细胞系 | |
| WO2011112090A2 (en) | Method for identifying variant rep protein encoding nucleic acids | |
| ES2734355T3 (es) | Vectores de baculovirus que comprenden secuencias de codificación repetidas con sesgos de codones diferenciales | |
| ES2575990T3 (es) | Vectores con codón de iniciación modificado para la traducción de aav-rep78 para la producción de aav en las células de insectos | |
| HK1249136B (en) | Improved aav vectors produced in insect cells |